THE APPLICATION PERIOD FOR THE 2018-2019 NIH CAP IS NOW CLOSED AND WILL REOPEN FOR 2019-2020 IN JULY/AUGUST 2019.
The National Institutes of Health (NIH) Commercialization Accelerator Program (CAP)
is a nationwide program funded by NIH and managed by Larta, Inc. The goal of CAP is to assist some of the most promising small life science and healthcare companies in bringing their technologies to market.
The program is customized to meet the needs of participating companies in three distinct tracks, each different in its objectives and outcomes: The Commercialization Transition Track (CTT) for emerging companies, the Advanced Commercialization Track (ACT), and the Regulatory/Reimbursement Training Track (RTT) for “seasoned” companies. The available slots will be distributed among the three tracks, and it should be noted that a participant company may only be accepted into one of the three tracks.
- Commercialization Transition Track (CTT) - Applicable to the majority of HHS SBIR/STTR Phase II awardees, this track provides support to develop tools to create a solid action plan with timelines, budgets, and outcomes pertinent to the stage and background of each participant company and to receive critical feedback from industry experts at a live session. For example, it is aimed at assisting participants with evaluating their commercialization options based on their specific technologies (including the need and prospect for investment, strategic partnerships, or licensing) and to develop a solid market-entry plan ("Commercialization Roadmap" or “Strategic Action Plan”) covering an 18-month period. It also assists participants in the development of market-appropriate tools to accomplish these objectives and provides opportunities for direct industry feedback. Participants work one-on-one with a principal advisor and industry experts as needed.
- Advanced Commercialization Track (ACT) - Applicable to those applicants with previous commercialization experience and/or have generated and managed revenue streams from commercial products and services, this track will focus (with the help of an “Expert Resource” (ER)) on a specific “high value” gap or issue that needs resolution in order to accelerate commercialization of a technology. For example, they may need to address a specific applicable issue (such as a license-focused IP strategy or a term sheet for investors) whose resolution is key to their continued growth. This track specifically deploys domain experts to help participants achieve these outcomes.
- Regulatory/Reimbursement Training Track (RTT) – Applicable to those seasoned applicants with previous commercialization experience, this track will apply to a selected group of HHS-funded companies seeking regulatory approval by the Food and Drug Administration (FDA) or seeking reimbursement from CMS (Centers for Medicare & Medicaid Services) and private insurance to achieve payment for products/services provided. As in the Advanced Commercialization Track (ACT), this track will focus (with the help of an “Expert Resource” (ER)) on developing a regulatory or reimbursement outcome (a framework and/or approach).
NOTE: NIH will not provide additional funding covering your participation in CAP; however, participants with a current active Phase II SBIR or STTR award may re-budget funds within the total costs awarded to cover allowable travel expenses for CAP events without NIH prior approval unless the re-budgeting action constitutes a change in scope or if the terms of award prohibit the use of funds for this purpose. Selected companies are encouraged to contact their funding NIH institute program officer for inquires in this regard.